Search

everythinglearnresearchcommunity

for

Search:↓

Diphencyprone is effective for treating patchy hair loss in alopecia areata, but tacrolimus is not.

Topical immunotherapy is more effective than dapsone for treating severe alopecia areata.

Some patients with severe alopecia areata developed skin darkening from their treatment, which may indicate a less effective response to the therapy.

Contact immunotherapy helped hair regrow in a patient with both alopecia and psoriasis.

Topical corticosteroids can help treat severe alopecia areata when other treatments fail.

Poor response to topical immunotherapy in alopecia areata patients is linked to impaired cell responses.

Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.

Contact immunotherapy can cause vitiligo in patients with autoimmune conditions.

Topical immunotherapy with DPCP led to some hair regrowth in most pediatric alopecia areata patients, especially those with milder cases and longer treatment.

Alopecia areata was successfully treated with contact immunotherapy, oral antihistamines, and topical corticosteroids.

Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.

Tumor immunotherapy can cause hair loss by disrupting hair follicle immunity.

Targeted immunotherapies may offer better treatment for alopecia areata by controlling inflammation and immune responses.

Hair Booster helps regrow hair by providing essential nutrients to fix internal imbalances.

Hair Booster helps regrow hair by providing essential nutrients and correcting internal imbalances.

Topical immunotherapy can help with severe hair loss, but results vary and need personalized, long-term treatment.

Atopic dermatitis in kids with alopecia areata can predict poor response to topical immunotherapy.

DPCP immunotherapy is effective for alopecia areata, and understanding influencing factors can improve treatment and satisfaction.

Systemic immunotherapies are used for immune-related hair loss but not usually for genetic hair loss, unless the patient has both conditions.

Diphenylcyclopropenone topical immunotherapy is effective for treating alopecia areata, with some side effects.

Contact immunotherapy might help treat various skin conditions, but more research is needed to confirm its safety and effectiveness.

Diphenylcyclopropenon treatment for Alopecia areata is effective and safe, improving patients' quality of life.

Topical immunotherapy for alopecia areata may work by creating immune cell clusters in the skin.

Topical immunotherapy with DPCP is most effective for certain alopecia areata types, with success linked to age and disease duration, and influenced by a gene polymorphism.

Selective immunotherapies like anifrolumab and belimumab are more effective for treating systemic lupus erythematosus than traditional drugs.

Some treatments that modify the immune system might help with certain types of hair loss but haven't been explored for common hair loss alone.

Nanomedicine-based immunotherapy shows promise in improving tissue repair and regeneration.

The document concludes that pregnancy and cancer share immune evasion tactics, but more research is needed before using checkpoint blockade immunotherapy in pregnant cancer patients to avoid harm to the placenta.

New targeted immunotherapies are improving treatment for inflammatory skin diseases.